Smoking cessation

Velocity Clinical Research begins European expansion with German site acquisition

Retrieved on: 
Wednesday, July 27, 2022
Running, Acquisition, Osteology, Urology, III, IV, Data collection, Dermatology, Research, Cros, Gastroenterology, Health, Pain management, Patient, Hypertension, Neurology, Internal medicine, Endocrinology, Smoking cessation, II, Vaccine, Pharmaceutical industry, Medical device, EU, Velocity

DURHAM, N.C., July 27, 2022 /PRNewswire/ -- Velocity Clinical Research ("Velocity"), the leading integrated research site organisation, today announces it has acquired its first European site, Clinical Research Hamburg, in Germany for an undisclosed amount.

Key Points: 
  • DURHAM, N.C., July 27, 2022 /PRNewswire/ -- Velocity Clinical Research ("Velocity"), the leading integrated research site organisation, today announces it has acquired its first European site, Clinical Research Hamburg, in Germany for an undisclosed amount.
  • "Velocity Clinical Research is breaking new ground for the clinical research industry.
  • As a result, Clinical Research Organizations and big pharmaceutical companies can benefit from simplified access to international clinical research.
  • Dr. Christine Grigat, Managing Director, Clinical Research Hamburg, commented, "Clinical Research Hamburg is known for being a high quality and successful dedicated research site.

Global Digital Therapeutic (DTx) Market Report to 2027 - Featuring 2Morrow, Better Therapeutics and Canary Health Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 6, 2022
Managed Care, Health Technology, Health, Ansoff Matrix, Porter's five forces analysis, Musculoskeletal disorder, USD, Smoking cessation, Single-frequency network, Impact, Competitive analysis, Global digital divide, Geography, COVID-19, Market development, Growth, Industry, Device tracking software, Risk, Medicine, Investment, CAGR, Diabetes, Cardiovascular disease, Neurological disorder, Component, SWOT, Observation, Emotion, Chronic Respiratory Disease, Pharmaceutical industry, Retail, Risk management, Marketing, Medical device, Distribution, Software, Obesity

Market dynamics are forces that impact the prices and behaviors of the Global Digital Therapeutic (DTx) Market stakeholders.

Key Points: 
  • Market dynamics are forces that impact the prices and behaviors of the Global Digital Therapeutic (DTx) Market stakeholders.
  • The report presents a detailed Ansoff matrix analysis for the Global Digital Therapeutic (DTx) Market.
  • The report analyses the Global Digital Therapeutic (DTx) Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Digital Therapeutic (DTx) Market.

Smoking Cessation & Nicotine De-Addiction Product Market to Reach $4.56 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 1, 2022
Health, Other Health, Online, Nicotine replacement therapy, Electronic cigarette, Drug therapy problems, USD, Nicotine, COVID-19, Bupropion, Research report, Smoking cessation, Nicotine gum, Pharmacy, CAGR, Pharmacy Council of India, Tablet, Drug, Pharmacotherapy, Hospital, Compound annual growth rate, State, Tobacco, Varenicline, Varenicline

The "Smoking Cessation & Nicotine De-Addiction Product Market Research Report by Product (Drug Therapy, E-Cigarettes, and Nicotine Inhalers), Distribution, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Smoking Cessation & Nicotine De-Addiction Product Market Research Report by Product (Drug Therapy, E-Cigarettes, and Nicotine Inhalers), Distribution, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • The United States Smoking Cessation & Nicotine De-Addiction Product Market size was estimated at USD 2,618.45 million in 2021 and expected to reach USD 2,882.28 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.69% to reach USD 4,562.44 million by 2027.
  • This research report categorizes the Smoking Cessation & Nicotine De-Addiction Product to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Product, the market was studied across Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, and Nicotine Sublingual Tablets.
  • The Nicotine Replacement Therapies is further studied across Nicotine Gums, Nicotine Lozenges, Nicotine Sprays, and Nicotine Transdermal Patches.

TravelCenters of America Announces Start of Annual Round Up Campaign to Support the St. Christopher Truckers Relief Fund

Retrieved on: 
Wednesday, June 29, 2022
Mobile, Wireless, Oil, Gas, Other Travel, Energy, General Automotive, Transportation, Technology, Automotive, Travel, Trucking, Transport, Other Automotive, Petro, Insurance, TravelCenters of America, ST, Man, TA, FORCE America, Inc., Smoking cessation, Round Up, Country, Woman, Eta, SCF, Health, Rail transport

TravelCenters of America Inc. (Nasdaq: TA), nationwide operator and franchisor of the TA, Petro Stopping Centers and TA Express travel center network, is once again supporting the St. Christopher Truckers Relief Fund , or SCF, with its annual Round Up campaign.

Key Points: 
  • TravelCenters of America Inc. (Nasdaq: TA), nationwide operator and franchisor of the TA, Petro Stopping Centers and TA Express travel center network, is once again supporting the St. Christopher Truckers Relief Fund , or SCF, with its annual Round Up campaign.
  • TA has been supporting SCF since 2010, raising more than $3 million dollars through campaigns and initiatives, including the Round Up campaign, which is now in its third year.
  • Drivers both at home and on the road need our support and the support of our amazing partners and sponsors.
  • The St. Christopher Truckers Relief Fund (SCF) helps over-the-road semi-truck drivers and their families who are out of work due to a recent illness or injury.

The VOOPOO van is back on the move

Retrieved on: 
Tuesday, June 28, 2022
Smoking, Herbal cigarette, Smoking cessation, IP68, Engineering, ITO, Mouth, Technology, Dust, Child, Time, TPP

VOOPOO also stands committed to helping every smoker in the UK find a comfortable and easy way to say goodbye to cigarettes for good.

Key Points: 
  • VOOPOO also stands committed to helping every smoker in the UK find a comfortable and easy way to say goodbye to cigarettes for good.
  • VOOPOO has run many campaigns aimed at helping smoking cessation, and its overarching motto being Stop Smoking, Choose VOOPOO.
  • Last month, VOOPOO also saw the launch of its next generation of large durable vape mods, the Argus GT2.
  • VooPoo has now partnered with Bestway ensuring that as many people as possible will be able to buy VooPoo devices, with its reach of 70,000 independent retailers that it stocks this will ensure VooPoo devices will be available to even more people moving forward!

The VOOPOO van is back on the move

Retrieved on: 
Tuesday, June 28, 2022
Smoking, Herbal cigarette, Smoking cessation, IP68, Engineering, ITO, Mouth, Technology, Dust, Child, Time, TPP

VOOPOO also stands committed to helping every smoker in the UK find a comfortable and easy way to say goodbye to cigarettes for good.

Key Points: 
  • VOOPOO also stands committed to helping every smoker in the UK find a comfortable and easy way to say goodbye to cigarettes for good.
  • VOOPOO has run many campaigns aimed at helping smoking cessation, and its overarching motto being Stop Smoking, Choose VOOPOO.
  • Last month, VOOPOO also saw the launch of its next generation of large durable vape mods, the Argus GT2.
  • VooPoo has now partnered with Bestway ensuring that as many people as possible will be able to buy VooPoo devices, with its reach of 70,000 independent retailers that it stocks this will ensure VooPoo devices will be available to even more people moving forward!

Older Adults Engaged in Digital Health Programs Successfully Lost Weight

Retrieved on: 
Tuesday, May 31, 2022
Digital, Lark, Population, Conditional sentence, AI, Certification, Fast Company, Wellness, Population Health Management, Patient, Weight loss, Lark Health, Health, Business Insider, Health care, Trial of the century, Research, Literature, Frontiers, Smoking, R&D, Program, Digital health, Anxiety, Smoking cessation, CDC, CB Insights, Center, Acquisition, Korea Disease Control and Prevention Agency, Curriculum, Prevalence, Topical steroid withdrawal, GLOBE, Medical device

In their analysis, researchers found that CDC qualifier study participants, who had an average age of 67.5, achieved an average weight loss of 8.56 percent, indicating that older adults had success with their weight loss goals when they engaged with either of Larks two AI-powered prevention programs.

Key Points: 
  • In their analysis, researchers found that CDC qualifier study participants, who had an average age of 67.5, achieved an average weight loss of 8.56 percent, indicating that older adults had success with their weight loss goals when they engaged with either of Larks two AI-powered prevention programs.
  • The results from this study suggest that older adults can successfully lose weight using fully digital programs like Larks.
  • This research adds to the growing body of literature on older adults and digital health, further suggesting that greater engagement is associated with positive health outcomes among this population.
  • In February, a study in Population Health Management found that Larks digital Diabetes Prevention Program increased access for individuals living in rural and federally designated Health Professional Shortage Areas, and previously a study in Frontiers of Digital Health showed high engagement among adults 65 years and older with Larks digital health platform.

CarolinaEast Medical Center Among Nation's Top Performing Hospitals for Treatment of Heart Attack Patients

Retrieved on: 
Friday, May 20, 2022
VCU Medical Center, Achievement, FACC, Thrombus, Guideline, American College, Cardiology, Cardiac rehabilitation, Aspirin, Patient, CarolinaEast Health System, Health, American College of Cardiology, Centers for Disease Control and Prevention timeline, Smoking cessation, Life, Cath lab, Hospital, Platinum, Safety, College, Muscle tissue, Coronary artery disease, Center, Pharmaceutical industry, Medical device, MD

NEW BERN, N.C., May 20, 2022 /PRNewswire/ -- CarolinaEast Medical Center has received the American College of Cardiology's NCDR Chest Pain – MI Registry Platinum Performance Achievement Award for 2022. CarolinaEast is one of only 240 hospitals nationwide to receive this honor. The award recognizes CarolinaEast's commitment and success in implementing a higher standard of care for heart attack patients and signifies that CarolinaEast has reached an aggressive goal of treating these patients.

Key Points: 
  • The award recognizes CarolinaEast's commitment and success in implementing a higher standard of care for heart attack patients and signifies that CarolinaEast has reached an aggressive goal of treating these patients.
  • A heart attack occurs when a blood clot in a coronary artery partially or completely blocks blood flow to the heart muscle.
  • "The receipt of this award indicates that CarolinaEast remains committed to providing top quality, guideline-driven care for heart attack patients.
  • CarolinaEast also boasts an American College of Cardiology accredited Chest Pain Center, HeartCARE Center, Cath Lab and Heart Failure program.

Lark Health Adds Former Evernorth and Salesforce Executives to Leadership Team

Retrieved on: 
Tuesday, May 3, 2022
Shannon, Smoking cessation, Senior, Express Scripts, Health care, Fast Company, Woman, Lark Health, Coronary artery disease, Clinical research, CB Insights, Weight loss, Cigna, Moyamoya disease, CDC, Salesforce, Patient, Certification, Health information exchange, Program, Industry, Anxiety, Roche Diagnostics, Edwards Lifesciences, Education, Leadership, MD, R&D, Government, Chronic condition, Female, Lark, CEO, VP, Business Insider, Entrepreneurship, AI, Acquisition, Digital, General manager, Management, Medical device, Renewable energy

MOUNTAIN VIEW, Calif., May 3, 2022 /PRNewswire/ -- Lark Health today announced it has appointed Lynne Nowak, MD, as Chief Medical Officer and Shannon Marques as Senior Vice President of Revenue Operations. Dr. Nowak and Marques are tasked with leading Lark's clinical and operational growth and helping guide the company as it continues to build momentum across key markets.

Key Points: 
  • Previously, Shannon served as the Vice President of Sales in the Healthcare and LifeSciences sector for Salesforce, where she grew a successful healthcare payer sales team.
  • As the company continues to expand, Lark remains committed to building a team that reflects the diversity of the populations it serves.
  • "I am thrilled to have Dr. Nowak and Shannon join our leadership team at Lark," says Julia Hu, CEO and Co-Founder of Lark Health.
  • Earlier this month, the company announced that it is now supporting simplified care management for Salesforce health plan customers and their members.

Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 2, 2022
AXS-05, CRL, Narcolepsy, Chemistry, Excessive daytime sleepiness, OSA, Safety, Depression, MDD, Fibromyalgia, Migraine, Central nervous system, Disease, Jazz Pharmaceuticals, AD, SYMPHONY, Smoking cessation, NASDAQ, Company, DCC, Patient, Clinical trial, FDA, New Drug Application, Breakthrough therapy, Research, Priority review, Therapy, ACCORD, EDS, Obstructive sleep apnea, NDA, Physician, Endpoint security, Central nervous system disease, Agitation, Dopamine, MD, R, Lists of diseases, CMC, Growth, Acquisition, CNS, NMDA, GEMINI, Food and Drug Administration, Food, Review, Webcast, Adult, Wakefulness, ID, G&A, Reboxetine, ASCEND, Pharmaceutical industry, Risk management, Bank, Online gambling, Solriamfetol, Alzheimer's disease, COVID-19

NEW YORK, May 2, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • NEW YORK, May 2, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2022.
  • Based on this interaction, the Company anticipates potential FDA action on the NDA in the second quarter of 2022.
  • The Company is evaluating the design of the study and will provide an update following consultation with the FDA.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss first quarter 2022 financial results as well as to provide a corporate update.